Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

45 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial.
Zhu AX, Park JO, Ryoo BY, Yen CJ, Poon R, Pastorelli D, Blanc JF, Chung HC, Baron AD, Pfiffer TE, Okusaka T, Kubackova K, Trojan J, Sastre J, Chau I, Chang SC, Abada PB, Yang L, Schwartz JD, Kudo M; REACH Trial Investigators. Zhu AX, et al. Among authors: kubackova k. Lancet Oncol. 2015 Jul;16(7):859-70. doi: 10.1016/S1470-2045(15)00050-9. Epub 2015 Jun 18. Lancet Oncol. 2015. PMID: 26095784 Clinical Trial.
Clinical and laboratory prognostic factors in patients with metastatic renal cell carcinoma treated with sunitinib and sorafenib after progression on cytokines.
Poprach A, Pavlik T, Melichar B, Kubackova K, Bortlicek Z, Svoboda M, Lakomy R, Vyzula R, Kiss I, Dusek L, Buchler T; Czech Renal Cancer Cooperative Group. Poprach A, et al. Among authors: kubackova k. Urol Oncol. 2014 May;32(4):488-95. doi: 10.1016/j.urolonc.2013.09.011. Epub 2013 Dec 8. Urol Oncol. 2014. PMID: 24321257
Outcomes for Patients with Metastatic Renal Cell Carcinoma Achieving a Complete Response on Targeted Therapy: A Registry-based Analysis.
Buchler T, Bortlicek Z, Poprach A, Pavlik T, Veskrnova V, Honzirkova M, Zemanova M, Fiala O, Kubackova K, Slaby O, Svoboda M, Vyzula R, Dusek L, Melichar B; Czech Renal Cancer Cooperative Group. Buchler T, et al. Among authors: kubackova k. Eur Urol. 2016 Sep;70(3):469-75. doi: 10.1016/j.eururo.2015.12.031. Epub 2015 Dec 30. Eur Urol. 2016. PMID: 26746623
Phase I/II clinical trial of dendritic-cell based immunotherapy (DCVAC/PCa) combined with chemotherapy in patients with metastatic, castration-resistant prostate cancer.
Podrazil M, Horvath R, Becht E, Rozkova D, Bilkova P, Sochorova K, Hromadkova H, Kayserova J, Vavrova K, Lastovicka J, Vrabcova P, Kubackova K, Gasova Z, Jarolim L, Babjuk M, Spisek R, Bartunkova J, Fucikova J. Podrazil M, et al. Among authors: kubackova k. Oncotarget. 2015 Jul 20;6(20):18192-205. doi: 10.18632/oncotarget.4145. Oncotarget. 2015. PMID: 26078335 Free PMC article. Clinical Trial.
Efficacy of Sunitinib in Elderly Patients with Metastatic Renal Cell Carcinoma: Data from Real-World Clinical Practice.
Poprach A, Lakomy R, Bortlicek Z, Melichar B, Pavlik T, Slaby O, Vyzula R, Svoboda M, Kiss I, Studentova H, Zemanova M, Fiala O, Kubackova K, Dusek L, Hornova J, Buchler T; Czech Renal Cell Cancer Cooperative Group. Poprach A, et al. Among authors: kubackova k. Drugs Aging. 2016 Sep;33(9):655-63. doi: 10.1007/s40266-016-0390-1. Drugs Aging. 2016. PMID: 27541802
45 results